GlassScriptPhysician profile
Javid D Tavari
NPI 1669400602
$3,017.31
in general payments reported to CMS, 2019-2025
21 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $322 · 2021: $565 · 2022: $629 · 2023: $586 · 2024: $191 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $427.04 | 2019-2022 | |
| Amgen INC. | $361.58 | 2022-2023 | Otezla |
| Lilly USA, LLC | $281.35 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $273.96 | 2020-2025 | Botox |
| Galderma Laboratories, L.P. | $267.19 | 2022-2024 | Dysport |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.99 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Eisai INC. | $139.88 | 2020-2021 | |
| Amarin Pharma, INC. | $131.13 | 2020-2021 | |
| Merz North America, INC. | $122.56 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $118.37 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $116.43 | 2024-2025 | Zoryve |
| Almatica Pharma LLC | $94.38 | 2023-2024 | Loreev Xr, Teriparatide |
| Idorsia Pharmaceuticals US INC | $84.81 | 2022 | |
| Novo Nordisk INC | $69.57 | 2023-2025 | Wegovy, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $68.69 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $64.58 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $51.35 | 2024-2025 | Breztri, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $42.35 | 2022 | |
| Gilead Sciences, INC. | $32.53 | 2020 | |
| Phathom Pharmaceuticals, INC. | $30.98 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $25.59 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javid Tavari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.